INCY
NASDAQIncyte Corp.
SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological Resarch
Price$113.12-0.60 (-0.53%)
01:30 PM07:45 PM
News · 26 weeks107+120%
2026-04-192026-10-11
Mix4090d
- Insider23(57%)
- Other10(25%)
- SEC Filings3(8%)
- Earnings2(5%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- PRIncyte to Report Third Quarter Financial ResultsIncyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, October 29, 2026. The schedule for the press release and conference call/webcast is as follows: Q3 2026 Press Release: October 29, 2026, at 7:00 a.m. ET Q3 2026 Conference Call: October 29, 2026, at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13763051 If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is
- PRKnight Therapeutics Announces Regulatory Approval of NIKTIMVO® in BrazilMONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1 "For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class mechanism that targets the underlyin
- INSIDERSEC Form 4 filed by Incyte Corp.4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Baker Bros. Advisors Lp was granted 644 shares (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Clancy Paul J was granted 203 shares, increasing direct ownership by 0.79% to 25,838 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERDirector Harrigan Edmund was granted 206 shares, increasing direct ownership by 0.89% to 23,225 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- PRMiniMed appoints Sheila Denton as General Counsel & Corporate SecretaryNORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary. "Sheila brings deep board experience, strong regulatory and transactional judgment, and a proven ability to build and lead high-performing global teams," said Que Dallara, Chief Executive Officer of MiniMed. "Her experience advising companies through periods of growth and transformation will make her a strong partner to our executive team and Board as we continue to scale MiniMed as an independent public company.""I'm excited to
- PRMirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP -Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month -PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 y
- INSIDEREVP, Chief Strategy Officer Gardner David H covered exercise/tax liability with 920 shares, decreasing direct ownership by 5% to 15,904 units (SEC Form 4) to satisfy withholding tax4 - INCYTE CORP (0000879169) (Issuer)
- PRIncyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity PortfolioIncyte (NASDAQ:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient ex
- PRSpecialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in AustraliaSINGAPORE, Sept. 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ:INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia. Ruxolitinib (1.5%) cream is a novel, topical Janus kinase (JAK) inhibitor.[1] In the U.S., OPZELURA is indicated for the topical treatment of non-segmental vitiligo in adults and pediatric patients 12 years of age and older, as well as for the topical short-
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J exercised 23,218 shares at a strike of $66.39 and sold $2,797,629 worth of shares (23,218 units at $120.49) (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- PRIncyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: 21st Annual Wells Fargo Healthcare Conference on Wednesday, September 9, 2026 at 11:00 a.m. EDT Cantor Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 9:45 a.m. EDT Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 at 12:20 p.m. EDT The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless foc
- SECIncyte Corp. filed SEC Form 8-K: Other Events8-K - INCYTE CORP (0000879169) (Filer)
- PRKnight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in BrazilMONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Projec
- INSIDEREVP, Human Resources Basi Ramitpal K covered exercise/tax liability with 504 shares, decreasing direct ownership by 4% to 10,993 units (SEC Form 4) (withholding obligation)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J sold $1,356,174 worth of shares (10,801 units at $125.56), decreasing direct ownership by 6% to 183,200 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- ANALYSTCanaccord Genuity initiated coverage on Incyte with a new price targetCanaccord Genuity initiated coverage of Incyte with a rating of Buy and set a new price target of $152.00
- PRIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Incyte Corporation (NASDAQ:INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company’s common stock and stock option awards to purchase an aggregate of 18,172 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of August 3, 2026, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU vests as to 25% of the shar
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J sold $1,305,422 worth of shares (10,640 units at $122.69), decreasing direct ownership by 5% to 204,804 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mayes Patrick A exercised 2,207 shares at a strike of $106.47 and sold $273,646 worth of shares (2,207 units at $123.99) (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDERPresident, Global Head of R&D Cagnoni Pablo J sold $1,901,794 worth of shares (15,888 units at $119.70), decreasing direct ownership by 7% to 215,444 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- INSIDEREVP & Chief Scientific Officer Mayes Patrick A exercised 45,767 shares at a strike of $78.48 and sold $5,734,376 worth of shares (47,954 units at $119.58), decreasing direct ownership by 3% to 61,441 units (SEC Form 4)4 - INCYTE CORP (0000879169) (Issuer)
- PRNew Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBSMinjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).[1],[2]In the pivotal Phase 3 inMIND clinical trial, patients with R/R FL receiving the Minjuvi combination regimen experienced a significant improvement in progression-free survival, with a 57% reduction in the risk of disease progression, relapse or death, compared with placebo plus lenalidomide and rituximab.[3]Follicular lymphoma is the second most common non-Hodgkin lymphoma (NHL), with
- PROpzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic DermatitisThe European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24, and was well tolerated 1,2,3 Incyte (NASDAQ:INCY) today announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. "The European Commission's approval of Opzelura is an important milestone for adults in Europe living with moderate atopic dermatitis
INCY FAQ
6 questionsWhat does Incyte Corp. do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial...Where does INCY stock trade?
Incyte Corp. (INCY) is listed on NASDAQ.What sector and industry is INCY in?
Incyte Corp. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.What are analysts saying about INCY?
Incyte Corp. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-08-20.What companies are similar to INCY?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), MEDP (Medpace Holdings Inc.), PPD (PPD, Inc.), CRL (Charles River Laboratories International Inc.), ICLR (ICON plc). Compare INCY side-by-side with any of them on Quantisnow.How can I track INCY on Quantisnow?
Quantisnow aggregates Incyte Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INCY to receive live email and push alerts on every new disclosure.